Shots:
United Therapeutics has acquired Thymmune Therapeutics, incl. its lead asset THY-100, developed for the treatment of congenital athymia
Under the deal, United Therapeutics has acquired Thymmune for $140M upfront, with up to $160M in additional earn-out payments tied to clinical & regulatory milestones through 2031
THY-100 is a preclinical regenerative therapy for congenital athymia…
Hair restoration sits at an unusual intersection of dermatology, surgery, and regenerative medicine. For most of the past two decades the category attracted limited industry attention in India, growing in pockets rather than as a structured specialty. That has changed. The discipline has matured into a recognisable healthcare segment with consolidating clinical standards, identifiable centres of excellence, and a…

